摘要
背景:与瑞典突变(Appswe)和外显子9缺失早产儿(Ps1dE9)共同表达人淀粉样前体蛋白的小鼠已成为目前应用最广泛的小鼠模型之一。 g阿尔茨海默病(AD)发病机制及AD治疗途径的临床前研究。 目的:系统研究APPswe/PS1dE9中的认知功能减退、淀粉样蛋白(Aβ-β,Aβ)沉积与脑或A型β水平的关系及其相互关系。 转基因小鼠。 方法:将APPswe/PS1dE9小鼠分为4、6、9、12个月龄组。我们评估了脑组织和血清中的认知能力、沉积的斑块以及Aβ40/Aβ42的水平。 不同年龄的老鼠。 结果:APPswe/PS1dE9小鼠从6月龄开始记忆能力下降,12个月时认知能力明显受损。巧合的是,淀粉样沉积开始在运输过程中发育。 6月龄NIC小鼠脑组织随年龄增加而增加。此外,APPswe/PS1dE9小鼠脑内Aβ42水平随年龄增加而升高,而Aβ40则无相应增加。血清Aβ42 DELI浓度 Ned在4~6个月大,但Aβ40无类似的年龄依赖性下降。 结论:APPswe/PS1dE9转基因小鼠在6月龄开始发育淀粉样斑块,并表现出相应的空间学习能力障碍。血清Aβ42水平显著下降 Ly期为4~6个月,A期β42开始在脑内积聚,并以斑块的形式沉积。
关键词: 阿尔茨海默病,淀粉样沉积,APPswe/PS1dE9转基因小鼠,脑Aβ42,认知功能减退,血清Aβ42。
Current Alzheimer Research
Title:Progressive Spatial Memory Impairment, Brain Amyloid Deposition and Changes in Serum Amyloid Levels as a Function of Age in APPswe/PS1dE9 Mice
Volume: 15 Issue: 11
关键词: 阿尔茨海默病,淀粉样沉积,APPswe/PS1dE9转基因小鼠,脑Aβ42,认知功能减退,血清Aβ42。
摘要: Background: Mice co-expressing human amyloid precursor protein with the Swedish mutation (APPswe) and exon-9-deleted presenilin (PS1dE9) has become one of the most widely used mouse models for studying Alzheimer’s disease (AD) pathogenesis and preclinical studies of AD therapeutic approaches.
Objective: In this study, we systematically investigated cognitive decline, amyloid-β (Aβ) deposition and cerebral or Aβ serum levels as well as the relationships among these measures in APPswe/PS1dE9 transgenic mice.
Method: APPswe/PS1dE9 mice were separated into four equal age cohorts (4, 6, 9, and 12 months). We assessed cognitive capacity, deposited plaques, and the levels of Aβ40/Aβ42 in brain tissue and serum of mice at different ages.
Results: APPswe/PS1dE9 mice exhibited declined memory beginning at 6 months of age, with cognitive capacity remarkably impaired at 12-months. Coincidently, amyloid deposits began to develop in transgenic mice brain at 6-months and increased with age. In addition, Aβ42 levels in brains of APPswe/ PS1dE9 mice increased with age with no parallel increase in Aβ40. The concentration of serum Aβ42 declined from 4 to 6 months of age, but a similar age-dependent decrease was not observed for Aβ40.
Conclusion: APPswe/PS1dE9 transgenic mice began to develop amyloid plaques at 6 months of age and exhibited a corresponding impairment of spatial learning capacity. Serum Aβ42 level decreased remarkably from 4 to 6 months, at which stage Aβ42 began to accumulate in the brain and deposit as plaques.
Export Options
About this article
Cite this article as:
Progressive Spatial Memory Impairment, Brain Amyloid Deposition and Changes in Serum Amyloid Levels as a Function of Age in APPswe/PS1dE9 Mice, Current Alzheimer Research 2018; 15 (11) . https://dx.doi.org/10.2174/1567205015666180709112327
DOI https://dx.doi.org/10.2174/1567205015666180709112327 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epidermal Growth Factor Receptor Inhibitors: A New Prospective in the Treatment of Lung Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Targeting Hypoxia Inducible Factor-1α: A Novel Mechanism of Ginsenoside Rg1 for Brain Repair after Hypoxia/Ischemia Brain Damage
CNS & Neurological Disorders - Drug Targets Oxidative Stress and Neurodegenerative Diseases: A Neurotrophic Approach
Current Drug Targets The Role of Glucose in the Pathogenesis of Alzheimers Disease Revisited:What Does it Tell us About the Therapeutic use of Lithium?
Central Nervous System Agents in Medicinal Chemistry Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay
Current Drug Targets Non-Antidepressant Treatment of Generalized Anxiety Disorder
Current Clinical Pharmacology The Relationship between Social Cognition and Executive Functions in Alzheimer’s Disease: A Systematic Review
Current Alzheimer Research Therapeutic Hypothermia for Cardiopulmonary Resuscitation: Why, When and How
Current Cardiology Reviews A Short Historical Survey of Developments in Amyloid Research
Protein & Peptide Letters Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Synthesis, Characterization and Evaluation of pH-sensitive Polyacrylamide- g-acacia Gum Microspheres for Colon Targeted Drug Delivery Application
Drug Delivery Letters Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies Depression, Serotonin and Tryptophan
Current Pharmaceutical Design Amyloid and Tau Positron Emission Tomography in Suggested Diabetesrelated Dementia
Current Alzheimer Research Psychopathological and Psychosocial Repercussions of Suicide in the Family
Current Psychiatry Research and Reviews Preconcentration and Determination of Solifenacin Using Hollow Fiber Microextraction Coupled with HPLC
Current Analytical Chemistry The Endocannabinoid System: A New Molecular Target for the Treatment of Tobacco Addiction
CNS & Neurological Disorders - Drug Targets Serotonergic Modulation of Spinal Sensory Circuits
Current Topics in Medicinal Chemistry Subject Index to Volume 1
Current Alzheimer Research Integrated Genomic Analysis Revealed Associated Genes for Alzheimer’s Disease in APOE4 Non-Carriers
Current Alzheimer Research